preloader
Thursday, April 18, 2024
Follow us on :

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

  • EVX-01 is Evaxion's lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results
  • Principal investigator Professor Adnan Khattak will walk us through this study's encouraging results and explain its potential for revolutionizing cancer treatment

COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study's Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place on November 8 at 11:30 a.m. EST.

In this 30-minute-long event, Professor Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion's personalized cancer vaccines are trying to meet. After summarizing the promising results reported in the EVX-01 Phase 1 clinical trial, Adnan will dive into Evaxion's latest EVX-01 Phase 2 clinical update and how these appear to confirm the benefits previously observed for this innovative immunotherapy. In the end, a Q&A session will be held for anyone who wants to learn more about this study and its underlying technology.

Evaxion's Chief Executive Officer, Christian Kanstrup, commented: "‘This latest clinical update stands as a testament to Evaxion's unwavering dedication to transforming patients' lives through innovative and targeted immunotherapies. Despite initial skepticism surrounding our pioneering work in personalized cancer vaccines, we are now reaping consistently positive outcomes that we believe hold the promise to change the lives of melanoma patients." Reflecting on how these results may impact the oncology field in the near future, Christian added, "‘We firmly believe that our ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner